{"disease":{"id":"immune-checkpoint-therapy","name":"immune checkpoint therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06635954","title":"A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Oxford Biodynamics Inc.","has_results":false},{"nct_id":"NCT06337097","title":"STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":980,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06958432","title":"Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06958419","title":"Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":286,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06980389","title":"Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":176,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT04805099","title":"Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05609695","title":"Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06923345","title":"Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT05863260","title":"Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04659382","title":"Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT07230639","title":"Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT07339488","title":"Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Chuangzhen Chen","has_results":false},{"nct_id":"NCT05754203","title":"Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT07279077","title":"Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06446154","title":"Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04414969","title":"Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT05310305","title":"PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05273255","title":"Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Michael Scharl","has_results":false},{"nct_id":"NCT06076135","title":"Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Chuangzhen Chen","has_results":false},{"nct_id":"NCT04419441","title":"Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Ospedale Maggiore Di Trieste","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}